X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
https://www.forbes.com/sites/johnlamattina/2019/04/10/the-biopharmaceutical-cartel-and-high-drug-prices/#4fb4c4e6533c
http://www.fiercepharma.com/pharma-asia/japan-s-pmda-reviews-hep-b-risk-link-to-hep-c-therapies
http://www.raps.org/Regulatory-Focus/News/2016/05/03/24862/FDA-Calls-for-Head-to-Head-Trials-in-Revised-Draft-Guidance-on-Hepatitis-C-Drugs/
http://www.fiercepharmamarketing.com/story/gilead-meds-face-little-threat-hep-c-rivals-merck-bms-and-abbvie-analyst/2016-03-30
http://www.prnewswire.com/news-releases/abbvie-receives-chmp-positive-opinion-for-viekirax-ombitasvirparitaprevirritonavir-tablets--exviera-dasabuvir-tablets-without-ribavirin-for-the-treatment-of-chronic-hepatitis-c-in-genotype-1b-patients-with-compensated-cir-300226929.html
http://www.reuters.com/article/us-gilead-sciences-fda-hepatitis-idUSKCN0VP1UQ
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55800a-eng.php
Market Place
Share 
